Aura Biosciences, Inc. — 2021 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter report. Aura is a clinical-stage biotechnology company with no approved products and no product revenue. Its lead candidate, AU-011, is a virus-like drug conjugate being developed initially for choroidal melanoma.
Financial performance and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $25.2 million | $18.0 million |
| General and administrative expense | $10.1 million | $4.2 million |
| Total operating expenses and operating loss | $35.3 million | $22.2 million |
| Net loss | $35.3 million | $22.2 million |
| Net cash used in operating activities | $32.4 million | $24.3 million |
| Net cash used in investing activities | $2.1 million | $0.8 million |
| Net cash provided by financing activities | $166.3 million | $10.0 million |
| Cash and cash equivalents at year-end | $149.1 million | $17.4 million |
- Research and development costs rose 39%, mainly reflecting manufacturing development and increased personnel; general and administrative costs more than doubled, partly due to increased headcount and public-company expenses.
- Because Aura generated no revenue, operating margins are not meaningful. The company reported an accumulated deficit of $152.1 million.
- At year-end, current assets were $153.7 million and current liabilities were $7.3 million. Total liabilities were $7.7 million, including operating lease liabilities and an $83,000 warrant liability. The company reported no long-term debt.
- The November 2021 IPO raised approximately $86.9 million gross and $78.3 million net. The filing also reports $80.2 million net from Series E preferred stock and $7.0 million net from a Series D-2 preferred-stock tranche. Preferred shares converted to common stock upon the IPO.
- Management estimated that cash and cash equivalents would fund operations into 2024, based on its operating plan and assumptions. The financial-statement note separately states cash was expected to cover at least 12 months from the statements’ issuance date; neither estimate means the company is funded through product approval.
Business progress and material developments
- AU-011 is designed to target tumor-associated modified HSPGs and, after laser activation, cause tumor-cell death and a secondary immune response. Aura’s platform and its clinical benefits remain under development and have not been validated through pivotal trials.
- In the completed Phase 1b/2 intravitreal study, 56 patients were treated. At 12 months, the reported tumor-control rate was 54% across patients and doses; it was 60% among 20 patients with documented active growth and 64% among 14 such patients receiving the highest therapeutic regimen. The company also reported vision preservation in 86% of all treated patients and 71% of the 14-patient active-growth, highest-regimen subgroup.
- A Phase 2 dose-escalation study is evaluating suprachoroidal administration. Early cohorts were described as generally well tolerated; no serious treatment-related adverse events had been reported in the initial data. The company planned to present six-to-12-month data in the second half of 2022 and then select a route of administration for pivotal development.
- Aura planned to begin its first pivotal trial for primary choroidal melanoma in the second half of 2022. The proposed adaptive, randomized design included therapeutic-dose, low-dose and sham-control groups, with tumor-thickness growth rate as the planned primary endpoint. The company acknowledged that regulators could require both planned pivotal trials for approval.
- Additional plans included filing an IND for choroidal metastases and starting a Phase 1a trial of AU-011 in non-muscle-invasive bladder cancer in the second half of 2022, subject to regulatory acceptance; bladder-cancer Phase 1a data were targeted for 2023.
Outlook, risks and other notable items
- The filing provides development milestones, not financial guidance. Aura expected expenses and operating losses to rise as it advances clinical trials, manufacturing and public-company operations; it did not provide a clear forecast of future revenue or profitability.
- AU-011 is the company’s only product candidate to date, making its prospects highly dependent on clinical results, regulatory approval, and eventual market acceptance. No pivotal trial had been completed and no product had been commercialized.
- Key execution risks include clinical efficacy and safety uncertainty, rare-disease enrollment, the complexity of a biologic/device/laser combination, possible trial redesign or added studies, and manufacturing scale-up. Aura relied on third parties and reported single-source arrangements for key AU-011 manufacturing stages.
- The company cited the possibility of needing additional capital before approval. New financing could dilute shareholders, add debt restrictions, or require licensing or collaboration on less favorable terms.
- Reported intravitreal-study adverse events included ocular inflammation, transient increases in eye pressure, pigmentary changes, and two serious treatment-related vision-loss events. These results are from an early-stage study and are not proof of safety or efficacy in larger trials.
- COVID-19 had not materially affected the business by year-end, although Aura reported minor manufacturing delays from a vendor supply constraint and warned of potential effects on trials, suppliers and timelines. No material litigation was reported as of December 31, 2021.
- The company reported effective disclosure controls at year-end. The 10-K did not include management’s internal-control assessment or an auditor attestation, citing the transition period for newly public companies.
Important facts for investors to verify
- Whether the planned pivotal trials began on schedule, what final protocols and endpoints regulators accepted, and whether the reported early-stage efficacy findings were confirmed.
- Updated safety, tumor-control and vision-preservation results, including longer follow-up and outcomes for the small patient subgroups cited in the filing.
- Actual cash use, subsequent financing, and whether the stated runway assumptions remain reasonable as clinical and manufacturing costs increase.
- Progress and comparability of commercial-scale manufacturing, the status of backup suppliers, and any resulting regulatory or trial delays.
- Regulatory acceptance and execution of the proposed bladder-cancer and choroidal-metastases programs, and the company’s ability to fund them alongside the lead program.
- Whether market-size, reimbursement and commercialization assumptions are supported; all products remain investigational and the filing’s market estimates are not realized revenue.